Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kristina Jenei
Observed names:
Jenei, Kristina,
K. Jenei,
KRISTINA JENEI,
Kristina M. Jenei
Institutions:
London School of Hygiene & Tropical Medicine,
London School of Economics and Political Science
Observed institutions:
University of British Columbia,
University of California, San Francisco,
London School of Hygiene & Tropical Medicine,
World Health Organization,
Canadian Centre for Applied Research in Cancer Control,
London School of Economics and Political Science
show all 6
ORCID:
0000-0002-3635-5212
Observed ORCID:
0000-0002-3635-5212
OpenAlex ID:
A5080236064
Works
59
Awards
2
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
2022
·
Kristina Jenei
, Zeba Aziz
, et al.
·
The Lancet Global Health
·
86
Challenges and opportunities for graduate students in public health during the COVID-19 pandemic
2020
·
Kristina Jenei
, Chenoa Cassidy-Matthews
, et al.
·
Canadian Journal of Public Health
·
53
PDF
Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study
2023
·
Kristina Jenei
, Adam J N Raymakers
, et al.
·
The Lancet Oncology
·
52
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada
2021
·
Daniel E. Meyers
, Kristina Jenei
, et al.
·
JAMA Internal Medicine
·
48
PDF
Rethinking Representation and Diversity in Deliberative Minipublics
2020
·
Daniel Steel
, Naseeb Bolduc
, et al.
·
Journal of Deliberative Democracy
·
41
PDF
Regulatory decisions diverge over aducanumab for Alzheimer’s disease
2022
·
Mark P Lythgoe
, Kristina Jenei
, et al.
·
BMJ
·
38
PDF
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years
2021
·
Kristina Jenei
, Daniel E. Meyers
, et al.
·
JAMA Oncology
·
31
PDF
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
2024
·
Kristina Jenei
, Arianna Gentilini
, et al.
·
The Lancet Oncology
·
23
PDF
Improving the response to future pandemics requires an improved understanding of the role played by institutions, politics, organization, and governance
2023
·
Peter Berman
, Maxwell A. Cameron
, et al.
·
PLOS Global Public Health
·
19
PDF
Shortages of essential cancer medicines: who is responsible and what are the possible solutions?
2024
·
Kristina Jenei
, Mark P Lythgoe
, et al.
·
The Lancet Oncology
·
17
PDF
What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)
2022
·
Kristina Jenei
, Alyson Haslam
, et al.
·
BMJ Open
·
15
PDF
Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions
2021
·
Kristina Jenei
, Michael Burgess
, et al.
·
Journal of Cancer Policy
·
14
Measuring access to essential medicines in the sustainable development goals
2024
·
Kristina Jenei
, Veronika Wirtz
·
Bulletin of the World Health Organization
·
13
PDF
High US drug prices have global implications
2022
·
Kristina Jenei
, Vinay Prasad
, et al.
·
BMJ
·
13
The Timing of Cancer Drug Approvals in the United States and Europe
2022
·
Kristina Jenei
·
JAMA Network Open
·
12
PDF
Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada
2021
·
Kristina Jenei
, Stuart Peacock
, et al.
·
Current Oncology
·
12
PDF
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
2021
·
Adam J. N. Raymakers
, Kristina M. Jenei
, et al.
·
PharmacoEconomics
·
12
WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines
2024
·
Kristina Jenei
, Camille E G Glaus
, et al.
·
The Lancet
·
8
PDF
GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists
2023
·
Thomas Piggott
, Lorenzo Moja
, et al.
·
Journal of Clinical Epidemiology
·
8
PDF
The Delicate Balancing Act of Accelerated Approval for Cancer Medicines—Speed, Certainty, and Benefit
2025
·
Kristina Jenei
, Christopher M. Booth
·
JAMA Network Open
·
7
The Political Economy of the World Health Organization Model Lists of Essential Medicines
2025
·
KRISTINA JENEI
·
Milbank Quarterly
·
7
Cancer in the Commonwealth: a Lancet Oncology Commission
2026
·
Rifat Atun
, Bhawna Sirohi
, et al.
·
The Lancet Oncology
·
6
Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
2023
·
Kristina Jenei
, Daniel Meyers
, et al.
·
JAMA Network Open
·
6
PDF
CostPlus and implications for generic imatinib
2022
·
Kristina Jenei
, Mark P. Lythgoe
, et al.
·
The Lancet Regional Health - Americas
·
6
PDF
Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015–2020
2021
·
Kristina Jenei
, Adam Raymakers
, et al.
·
Journal of Cancer Policy
·
6
Show more works
View as search
Works count:
59
Citation count:
588
H-index:
13
I10-index:
17
Year
Topic
Type